Trial Summary:

The primary purpose of this trial is to evaluate the efficacy, safety and feasibility of alternating osimertinib and gefitinib for the treatment of EGFR-T790M mutation positive advanced non-small cell lung cancer.

Supported By:

Astra Zeneca

Eligibility:

1. Adults, aged 18 years and older, with histologically or cytologically confirmed metastatic or unresectable locally advanced NSCLC 2. Prior therapy with an EGFR-TKI. Patients may also have received additional lines of treatment 3. Documented evidence of EGFR-T790M mutation on tissue and/or plasma sample following disease progression on the most recent EGFR-TKI therapy (T790M mutation status will need to be re-confirmed in the event of an alternative systemic treatment following progression on the most-recent EGFR-TKI therapy). 4. Measurable disease according to RECIST version 1.1. 5. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

Registration ID:

ACTRN12617000720314

Participation:

Australia

Australian Lead Group:

Status:

Closed

Activation Date:

07/10/2016

Chairs:

A/Prof Ben Soloman (Peter MacCallum Cancer Centre)

Contact:

oscillate.study@sydney.edu.au